论文部分内容阅读
目的:比较替加色罗与莫沙必利治疗糖尿病胃轻瘫的疗效。方法:65例糖尿病胃轻瘫患者随机分为治疗组(33例)及对照组(32例)。两组均予控制饮食、适宜运动,同时注射胰岛素或口服抗糖尿病药控制血糖。在此基础上,治疗组加用替加色罗片6 mg,po bid,对照组加用莫沙必利片5 mg,po tid。均为饭前30 min口服。两组疗程均为4周。观察两组4周后临床疗效及治疗后6个月、1年的复发率。结果:治疗4周后,治疗组总有效率为93.94%,明显优于对照组总有效率71.88%(P<0.05)。治疗组6个月和1年的复发率也明显低于对照组(P<0.05)。结论:替加色罗治疗糖尿病胃轻瘫临床疗效较好,明显降低复发率。
Objective: To compare the efficacy of tegaserod and mosapride in the treatment of diabetic gastroparesis. Methods: 65 patients with diabetic gastroparesis were randomly divided into treatment group (33 cases) and control group (32 cases). Both groups were to control the diet, suitable for exercise, while insulin or oral administration of anti-diabetic drugs to control blood sugar. On this basis, the treatment group plus tegaserod 6 mg, po bid, the control group plus mosapride 5 mg, po tid. All oral 30 min before meals. Two courses of treatment were 4 weeks. The clinical efficacy of the two groups after 4 weeks and the recurrence rate of 6 months and 1 year after treatment were observed. Results: After 4 weeks of treatment, the total effective rate in the treatment group was 93.94%, which was significantly better than that in the control group (71.88%, P <0.05). The recurrence rates at 6 months and 1 year in the treatment group were also significantly lower than those in the control group (P <0.05). Conclusion: The effect of tegaserod on diabetic gastroparesis is better and the relapse rate is obviously lower.